Zacks Investment Research lowered shares of Catabasis Pharmaceuticals (NASDAQ:CATB) from a buy rating to a hold rating in a report issued on Thursday morning.
According to Zacks, “Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
Other analysts also recently issued research reports about the company. Citigroup set a $3.50 price target on Catabasis Pharmaceuticals and gave the company a hold rating in a research note on Thursday, October 5th. CIBC reissued an outperform rating and issued a $7.00 price target (up previously from $4.00) on shares of Catabasis Pharmaceuticals in a research note on Thursday, October 5th. Oppenheimer raised their price objective on Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the company an outperform rating in a report on Thursday, October 5th. Wedbush restated an outperform rating and issued a $4.00 price objective on shares of Catabasis Pharmaceuticals in a report on Friday, December 15th. Finally, Cowen restated a market perform rating and issued a $2.00 price objective on shares of Catabasis Pharmaceuticals in a report on Friday, October 6th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $4.82.
Catabasis Pharmaceuticals (NASDAQ CATB) remained flat at $$1.53 on Thursday. 104,065 shares of the stock traded hands, compared to its average volume of 219,109. Catabasis Pharmaceuticals has a 1 year low of $1.08 and a 1 year high of $5.51. The stock has a market cap of $35.32, a price-to-earnings ratio of -1.01 and a beta of 1.26.
Catabasis Pharmaceuticals (NASDAQ:CATB) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.02. The firm had revenue of $0.25 million during the quarter. equities research analysts anticipate that Catabasis Pharmaceuticals will post -1.38 earnings per share for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in CATB. Oppenheimer & Co. Inc. grew its holdings in shares of Catabasis Pharmaceuticals by 33.3% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock valued at $169,000 after acquiring an additional 30,000 shares in the last quarter. Virtu KCG Holdings LLC bought a new position in shares of Catabasis Pharmaceuticals in the 2nd quarter valued at about $271,000. Finally, Wedbush Securities Inc. grew its holdings in shares of Catabasis Pharmaceuticals by 2,368.6% in the 3rd quarter. Wedbush Securities Inc. now owns 251,802 shares of the biotechnology company’s stock valued at $534,000 after acquiring an additional 241,602 shares in the last quarter. Institutional investors own 32.31% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/01/20/catabasis-pharmaceuticals-catb-downgraded-to-hold-at-zacks-investment-research-2.html.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.